Clinical Trial Update: Study Evaluating the Efficacy of DVS-233 in Fibromyalgia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial evaluating DVS-233 for fibromyalgia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia

Drugs mentioned

• DVS-233

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Fibromyalgia | Phase 2, Phase 3 | Status: TERMINATED